10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)
þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the Quarterly Period Ended September 30, 2013
Or
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the Transition Period From          to

Commission File No. 001-16381

_________________

Arrayit Corporation

(Exact name of registrant as specified in its charter)

_________________

Nevada	001-16381	76-0600966
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation or Organization)	File Number)	Identification No.)

524 East Weddell Drive, Sunnyvale, CA 94089

(Address of Principal Executive Offices) (Zip Code)

408-744-1331

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.001 par value per share

OTCQB

_________________

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes  o     No  þ

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.     Yes  o    No  þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  þ    No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes  þ    No  o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-Q or any amendment to this Form 10-Q.     Yes o     No  þ

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer  o Accelerated filer  o Non-accelerated filer  o Smaller reporting company  þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes o    No þ

As of November 7, 2013, there were 30,918,453shares of common stock outstanding.

Form 10-Q

For the Quarterly Period Ended September 30, 2013

TABLE OF CONTENTS

			Page
PART I. FINANCIAL INFORMATION
	Item 1.	Consolidated Financial Statements
		Consolidated Balance Sheets at September 30, 2013 (unaudited) and December 31, 2012(audited)		4
		Consolidated Statements of Operations for the three and nine months ended September 30, 2013 and 2012 (unaudited)		5
		Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and 2012 (unaudited)		6
		Notes to Consolidated Financial Statements		7
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		15
	Item 3.	Quantitative and Qualitative Disclosure About Market Risk		18
	Item 4.	Controls and Procedures		18
PART II. OTHER INFORMATION
	Item 1.	Legal Proceedings		19
	Item 1A.	Risk Factors		19
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		19
	Item 3.	Defaults Upon Senior Securities		19
	Item 4.	Removed and Reserved		19
	Item 5.	Other Information		19
	Item 6.	Exhibits		19
Signatures				20
Exhibit 31.1
Exhibit 31.2
Exhibit 32.1

2

This report contains trademarks and trade names that are the property of Arrayit Corporation and its subsidiaries, and of other companies, as indicated.

FORWARD-LOOKING STATEMENTS

Portions of this Form 10-Q, including disclosure under “Management’s Discussion and Analysis of Financial Position and Results of Operations,” contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. You should not unduly rely on these statements. Forward-looking statements involve assumptions and describe our plans, strategies, and expectations. You can generally identify a forward-looking statement by words such as may, will, should, expect, anticipate, estimate, believe, intend, contemplate or project. Factors, risks, and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, among others,

● our ability to raise capital,

● our ability to obtain and retain customers,

● our ability to provide our products and services at competitive rates,

● our ability to execute our business strategy in a very competitive environment,

● our degree of financial leverage,

● risks associated with our acquiring and integrating companies into our own,

● risks related to market acceptance and demand for our services,

● the impact of competitive services, and

● other risks referenced from time to time in our SEC filings.

With respect to any forward-looking statement that includes a statement of its underlying assumptions or bases, we caution that, while we believe such assumptions or bases to be reasonable and have formed them in good faith, assumed facts or bases almost always vary from actual results, and the differences between assumed facts or bases and actual results can be material depending on the circumstances. When, in any forward-looking statement, we or our management express an expectation or belief as to future results, that expectation or belief is expressed in good faith and is believed to have a reasonable basis, but there can be no assurance that the stated expectation or belief will result or be achieved or accomplished. All subsequent written and oral forward-looking statements attributable to us, or anyone acting on our behalf, are expressly qualified in their entirety by the cautionary statements. We do not undertake any obligations to publicly release any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect unanticipated events that may occur.

3

PART I – FINANCIAL INFORMATION

ITEM 1.

ARRAYIT CORPORATION

CONSOLIDATED BALANCE SHEETS

	09/30/2013 (unaudited)			12/31/2012
ASSETS
Current Assets:
Cash	$	807		$	518
Accounts receivable, net		346,460			227,743
Inventory		444,755			316,807
Prepaid expenses		2,250			2,250
Total current assets		794,272			547,318
Fixed assets, net		22,162			-
Deposits		18,365			18,365
Total assets	$	834,799		$	565,683
Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable and accrued liabilities	$	6,641,664		$	6,567,136
Bank overdraft		9,187			129,495
Due to related parties		525,533			577,033
Customer deposits		22,164			4,895
Notes payables, current portion including related parties		890,657			929,269
Total current liabilities		8,089,205			8,207,828
Notes payable, long term		-			-
Total liabilities		8,089,205			8,207,828
Commitments and contingencies		-			-
Stockholders' Deficit
Preferred stock,  $0.001 par value; 20,000,000 shares authorized;
Preferred stock, Series A, 22,034 shares outstanding		22			22
Preferred stock, Series C, $0.001 par value; 87,146 and 88,888 shares outstanding		87			89
Common stock, $0.001 par value; 480,000,000 shares authorized, 30,918,453 and 28,179,096 issued and outstanding		30,728			27,988
Additional paid-in capital		16,895,607			16,645,345
Accumulated deficit		(24,180,850	)		(24,315,589	)
Total stockholders’ deficit		(7,254,406	)		(7,642,145	)
Total liabilities and stockholders' deficit	$	(834,799	)	$	565,683

The accompanying notes are an integral part of these consolidated financial statements

4

ARRAYIT CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Statement of Operations	For the Three Months Ended Sept 30, 2013			For the Three Months Ended Sept 30, 2012			For the Nine Months ended Sept 30, 2013			For the Nine Months ended Sept 30, 2012
Total Revenues	$	829,201		$	547,233		$	2,374,789		$	1,850,935
Cost of Sales		522,211			252,003			1,354,619			966,185
Gross Margin		306,990			295,230			1,020,170			884,750
Selling, General and Administrative		259,885			297,745			744,475			2,037,425
Research and Development		8,934			771			10,149			26,221
Legal Expense		15,566			8,331			53,473			51,917
Income (loss) from operations		22,605			(11,617	)		212,073			(1,230,813	)
Interest expense		(57,086	)		(27,859	)		(249,039	)		(122,358	)
Gain on extinguishment of liabilities		6,168			-			171,702			-
Net income (loss)		28,313			(39,476	)		134,736			(1,353,171	)
Less: Net loss attributable to the non-controlling interest		-			(44,407	)		-			(460,813	)
Net Income (Loss) attributable to common stockholders		28,313			4,931			134,736			(892,358	)
Income (Loss) per share - basic	$	.00		$	.00		$	.00		$	(.03	)
Income (Loss) per share - diluted	$	.00		$	.00		$	.00		$	(.03	)
Basic weighted average number of common shares		30,085,700			27,803,584			28,948,749			27,434,176
Diluted weighted average number of common shares		61,290,190			27,803,584			59,838,501			27,434,176

The accompanying notes are an integral part of these consolidated financial statements

5

ARRAYIT CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	For the Nine Months Ended Sept 30
	2013			2012
Cash flows from operating activities:
Net income (loss)	$	134,736		$	(1,353,171	)
Adjustments to reconcile net income (loss)  to net cash provided by (used by) operating activities:
Depreciation		-			9,818
Stock paid for services		-			36,150
Gain on extinguishment of liabilities		(171,702	)		-
Increase in non-controlling interest		-			1,080,868
Bad debt recovery		(5,312	)		-
Provision for bad debt		38,962			-
Changes in operating assets and liabilities
Accounts receivable		(132,452	)		78,372
Inventory		(127,948	)		(172,053	)
Accounts payable and accrued liabilities		76,365			341,094
Bank overdraft		(120,308	)		26,456
Due to related parties		(51,500	)		(29,000	)
Accrued interest		250,838			70,388
Customer deposits		17,269			-
Net cash provided by (used in) operating activities		(91,052	)		88,922
Cash flows from investing activities:
Cash paid for purchase of fixed assets		(1,124	)		-
Net cash used in investing activities		(1,124	)		-
Cash flows from financing activities:
Proceeds from loans		-			-
Proceeds from issuance of common stock		193,000			-
Proceeds from notes payable		-			85,320
Repayment of notes payable		(100,535	)		(152,059	)
Net cash provided by (used by) financing activities		92,465			(66,739	)
Net increase in cash		289			22,183
Cash, beginning of period		518			1,519
Cash, end of period	$	807		$	23,702
Supplemental cash flow information:
Cash paid for interest	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements

6

ARRAYIT CORPORATION

NOTES TO CONSOLIDATED UNAUDITED STATEMENTS

September 30, 2013

NOTE 1 – ORGANIZATION AND BUSINESS OPERATIONS

Arrayit Corporation (the “Company” or “Arrayit”) is a Nevada “C” Corporation that entered into the life sciences industry in 1996.  Arrayit is a leading edge developer, manufacturer and marketer of next-generation life science tools and integrated systems for the large scale analysis of genetic variation, biological function and diagnostics. Using Arrayit’s proprietary and patented technologies, the Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping, gene expression and protein analysis markets, and the Company expects to enter the market for manufacturing molecular diagnostics.

Arrayit has earned respect as a leader in the health care and life sciences industries with its proven expertise in three key areas:  the development and support of microarray tools and components, custom printing and analysis of microarrays for research, and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states.  As a result, Arrayit has provided tools and services to thousands of the leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies worldwide.

Arrayit has a December 31 year end.

Arrayit’s principal office is in Sunnyvale, California. Arrayit presently has nine employees.

Interim financial statements

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X, and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ equity in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Arrayit’s Annual Report filed with the SEC on Form 10-K/A. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the consolidated financial statements, which would substantially duplicate the disclosures contained in the audited financial statements for fiscal year 2012 as reported in Form 10-K/A, have been omitted.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The following includes a description of subsidiaries and percentage ownership at September 30, 2013:

Subsidiary	Date of Incorporation	Business of Entity	Ownership
TeleChem International, Inc.	November 1, 1993	Import, export, manufacturing and distribution of wholesale industrial chemicals	100% owned by Arrayit Corporation
Arrayit Scientific Solutions, Inc.	October 15, 2009	Markets a test for Parkinson’s Disease incorporating the technology and equipment developed by Arrayit Corporation	98% owned by Arrayit Corporation and 2% owned by the former President of Arrayit Scientific Solutions, Inc.
Avant Diagnostics, Inc.	June 2, 2009	Markets a test for Ovarian Cancer incorporating the technology and equipment developed by Arrayit Corporation	42.9% owned by Arrayit Corporation

The Company had previously consolidated the financial statements of Avant Diagnostics, Inc. as a majority owned subsidiary and this is reflected in the unaudited consolidated financial statements for the three and nine months ended September 30, 2012.  On December 31, 2012, Avant Diagnostics, Inc. issued additional shares of its common stock which reduced the Company’s ownership interest in Avant Diagnostics, Inc. so that the Company no longer had a controlling financial interest.  In accordance with FASB ASC 810-10-40, “Deconsolidation of a Subsidiary or Derecognition of a Group of Assets”, as of December 31, 2012, the Company deconsolidated its majority ownership interest and recognized a non-cash, net gain on the transaction.  Thus, the Company’s September 30, 2013 unaudited financial statements do not include the effect of the financial statements of Avant Diagnostics, Inc.

In July 2013, the Company issued 500,000 shares of its common stock with a market price of $0.12 per share or $60,000 to settle debt of Avant Diagnostics, Inc.  Arrayit Corporation was the guarantor of the debt.  The Company recorded a charge of $38,962 on the transaction and received equipment from Avant Diagnostics, Inc. valued at $21,038.

On December 12, 2011, Arrayit Corporation signed an Agreement and Plan of Distribution with its subsidiary, Avant Diagnostics, Inc., whereby 19,350,000 shares of common stock of Avant Diagnostics (42.9% of the total outstanding) owned by Arrayit Corporation will be distributed ratably to the shareholders of Arrayit Corporation on the record date which will occur upon approval by the SEC of the Form S-1 registration statement to be submitted by Avant Diagnostics, Inc.

7

ARRAYIT CORPORATION

NOTES TO CONSOLIDATED UNAUDITED STATEMENTS

September 30, 2013

Summary of Significant Accounting Policies

Financial Reporting:

The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America. Revenues and expenses are reported on the accrual basis, which means that income is recognized as it is earned and expenses are recognized as they are incurred. Inventories are stated at the lower of cost or market, cost determined on the basis of FIFO. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured.

Management acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that 1) recorded transactions are valid; 2) valid transactions are recorded; and 3) transactions are recorded in the proper period in a timely manner to produce financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

Non-Controlling Interest:

The Company accounts for the non-controlling interest in its subsidiaries under ASC 810-10-45-16, Non-controlling Interest in a Subsidiary.  This standard defines a non-controlling interest, previously called a minority interest, as the portion of equity in a subsidiary not attributable, directly or indirectly, to a parent. The standard requires, among other items, that a non-controlling interest be included in the consolidated statement of financial position within equity separate from the parent's equity; consolidated net income to be reported at amounts inclusive of both the parent's and non-controlling interest’s shares and, separately, the amounts of consolidated net income attributable to the parent and non-controlling interest all on the consolidated statement of operations; and if a subsidiary is deconsolidated, any retained non-controlling equity investment in the former subsidiary be measured at fair value and a gain or loss be recognized in net income based on such fair value.  Additionally, the standard defines a non-controlling interest as a financial instrument issued by a subsidiary that is classified as equity in the subsidiary's financial statements.  A financial instrument issued by a subsidiary that is classified as a liability in the subsidiary's financial statements based on the guidance in other standards is not a controlling interest because it is not an ownership interest.

Recent Accounting Pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

Income/Loss per Common and Common Equivalent Share

The computation of basic income/loss per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents which would arise from their exercise using the treasury stock method and the average market price per share during the year.  The Company determined that the effect of common stock equivalents (Stock Options, Stock Warrants and convertible Series “C” Preferred Shares) outstanding at September 30, 2013 should be included in diluted earnings per common share for the nine months ended September 30, 2013.  The effect of common stock equivalents for the three months ended September 30, 2013 and for the periods in 2012 were anti-dilutive.

8

ARRAYIT CORPORATION

NOTES TO CONSOLIDATED UNAUDITED STATEMENTS

September 30, 2013

NOTE 3 – GOING CONCERN

The accompanying consolidated financial statements of the Company were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has large working capital and accumulated deficits. At September 30, 2013, Arrayit had a working capital deficit of $7,294,933 and an accumulated deficit of $24,180,850.  Management believes that current available resources will not be sufficient to fund the Company’s planned expenditures over the next 12 months. The Company’s ability to continue to meet its obligations and to achieve its business objectives is dependent upon, among other things, raising additional capital or generating sufficient revenue in excess of costs. At such time as the Company requires additional funding, the Company will seek to raise such additional funding from various possible sources, including its parent company, the public equity market, private financings, sales of assets, collaborative arrangements and debt. If the Company raises additional capital through the issuance of equity securities or securities convertible into equity, stockholders will experience dilution, and such securities may have rights, preferences or privileges senior to those of the holders of common stock or convertible senior notes. If the Company raises additional funds by issuing debt, the Company may be subject to limitations on its operations, through debt covenants or other restrictions. If the Company obtains additional funds through arrangements with collaborators or strategic partners, the Company may be required to relinquish its rights to certain technologies or products that it might otherwise seek to retain. There can be no assurance that the Company will be able to raise additional funds, or raise them on acceptable terms. If the Company is unable to obtain financing on acceptable terms, it may be unable to execute its business plan, the Company could be required to delay or reduce the scope of its operations, and the Company may not be able to pay off its obligations, if and when they come due.

These factors create substantial doubt about Arrayit’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability or classification of recorded assets and liabilities or other adjustments that may be necessary should the Company not be able to continue as a going concern.

The ability of Arrayit to continue as a going concern is dependent on Arrayit generating cash from the sale of its common stock or obtaining debt financing and attaining future profitable operations. Management's plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance Arrayit will be successful in these efforts.

NOTE 4 – ACCOUNTS RECEIVABLE

Accounts receivable are shown net of an Allowance for Doubtful Accounts.  As more fully explained in Note 5 below, accounts receivable has been reduced by Accounts Receivable loans sold with recourse.

	September 30, 2013			December 31, 2012
Gross accounts receivable	$	649,255		$	590,449
Less:
Allowance for doubtful accounts		(133,000	)		(133,000	)
Loan value of receivables sold   with recourse		(169,795	)		(229,706	)
Total	$	346,460		$	227,743

9

ARRAYIT CORPORATION

NOTES TO CONSOLIDATED UNAUDITED STATEMENTS

September 30, 2013

NOTE 5 – ACCOUNTS RECEIVABLE SOLD WITH RECOURSE

Pursuant to an agreement dated July 5, 2007, the Company has sold some of its Accounts Receivable to a financial institution with full recourse.  The financial institution retains a 15% portion of the proceeds from the receivable sales as reserves, which are released to the Company as the Receivables are collected.  The maximum commitment under this facility is $450,000, and is limited to receivables that are less than 31 days outstanding. The facility bears interest at 16% at September 30, 2013, and is secured by an unconditional guarantee of the Company and a first charge against the Accounts Receivable.  At September 30, 2013, the balance outstanding under the recourse contracts was $169,795 net of a hold back reserve of $164,769 (December 31, 2012, $229,706 net of a hold back reserve of $86,984).  Because of the Company’s credit policies, repossession losses and refunds in the event of default have not been significant and losses under the present recourse obligations are not expected to be significant, it is at least reasonably possible that the Company’s estimate will change within the near term.

NOTE 6 – FIXED ASSETS

Property and equipment consisted of the following:

	September 30, 2013			December 31, 2012
Fixed Assets – Cost	$	333,319		$	311,157
Less Accumulated Depreciation		(311,157	)		(311,157	)
Total	$	22,162		$	-

Depreciation expense totaled $0 and $9,818, respectively, for the nine months ended September 30, 2013 and 2012. 

NOTE 7 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities, consisted of the following:

	September 30, 2013		December 31, 2012
ACCOUNTS PAYABLE
Trade vendors	$	1,512,038	$	1,488,622
Professional advisors		2,979,852		3,059,594
Total Accounts Payable		4,491,890		4,548,216
ACCRUED LIABILITIES
Accrued salaries and wages		1,111,649		1,127,089
Judgment interest		628,698		482,404
Other		409,427		409,427
Total Accrued Liabilities		2,149,774		2,018,920
TOTAL	$	6,641,664	$	6,567,136

10

ARRAYIT CORPORATION

NOTES TO CONSOLIDATED UNAUDITED STATEMENTS

September 30, 2013

NOTE 8 – DEBT

	September 30, 2013		December 31, 2012
NOTES PAYABLE - ARRAYIT CORP.
Notes payable, interest at 10%, which was due August 10, 2010 and is now past due, secured by 1,000,000 shares out of the Company's common stock, pledged to the private lender without compensation by the Company's Chairman.  Interest is being accrued at 25% default rate.	$	305,938	$	275,000
Note payable, 0% interest, due on demand together with 75,000 shares in the form of common stock warrants		15,000		15,000
Notes payable, interest at 8%, unsecured due on demand from Arrayit creditors		31,082		30,749
Notes payable, interest at rates varying from 8% to 10%, unsecured due on demand from the former TeleChem shareholders and their families.		538,637		608,520
Total notes payable, including related parties	$	890,657	$	929,269
Short Term Debt	$	890,657	$	929,269
Long Term Debt	$	-	$	-

NOTE 9 – WARRANTS AND OPTIONS

The following table summarizes options and warrants outstanding at September 30, 2013:

	Number of Options and Warrants		Weighted Average Exercise Price Per Share
Outstanding at December 31, 2012		1,915,000	$	0.08
Granted		1,346,154	$	0.17
Cancelled/forfeited		-		-
Expired		1,265,000	$	.05
Exercised		650,000	$	.30
Outstanding at Sept 30, 2013		1,346,154	$	0.17

In June 2013, the Company completed a unit offering of its common stock. Subscribers purchased units at $0.13 per unit with each unit consisting of one share of common stock and a warrant to purchase an additional share at prices ranging from $0.15 to $0.18 per share for three years. The Company raised $175,000 and issued 1,346,154 shares of common stock and 1,346,154 warrants to purchase common stock under this offering. None of the warrants have been exercised.

11

ARRAYIT CORPORATION

NOTES TO CONSOLIDATED UNAUDITED STATEMENTS

September 30, 2013

In September 2013, a warrant holder exercised 650,000 warrants with exercise prices ranging from $0.20 to $0.35 per share and received 184,350 common shares through a cashless exercise at the market price of $0.42 per share.

At various dates during the quarter ended September 30, 2013, the Company agreed to issue 7,600,000 warrants to purchase shares of its common stock at prices ranging from $0.13 to $1.20 per share for three years. In November 2013, the 7,600,000 warrants were rescinded effective as of the date of their original issuance.  None of the warrants had been exercised.

NOTE 10 – ROYALTY OBLIGATIONS

The Parkinson’s Institute – ARRAYIT SCIENTIFIC SOLUTIONS, INC.

Pursuant to an agreement dated February 9, 2009 between the Company, and The Parkinson's Institute, a California Corporation, Arrayit Scientific Solutions, Inc. is obligated to make payments, of 5% of gross earnings generated from Research derived from the biological specimens from Parkinson's disease patients and control patients provided by the Parkinson's Institute.

There were no revenues generated during the fiscal periods ended September 30, 2013 and hence no obligation to pay any royalties to the Parkinson’s Institute.

NOTE 11 – STOCK-BASED COMPENSATION

The Company adopted ASC 718 and ASC 505, "Share-Based Payment", to account for its stock options and similar equity instruments issued.  Accordingly, compensation costs attributable to stock options or similar equity instruments granted are measured at the fair value at the grant date, and expensed over the expected vesting period.  ASC 718 and ASC 505 requires excess tax benefits be reported as a financing cash inflow rather than as a reduction of taxes paid.

Operations for the periods ended September 30, 2013 and September 30, 2012 include $0 and $36,150 of stock-based compensation, arising from the granting of 0 and 106,325 unregistered common shares, respectively.  Restricted shares were issued in exchange for services related to website consulting and investor relations. The Company relied upon the exemption under Section 4(2) of the Securities Act.

NOTE 12 – CONVERTIBLE PREFERRED STOCK

Convertible Preferred Stock

The Series A Preferred Stock has no stated dividend rate and has a liquidation preference of $.001 per share. The Series A Preferred Stock also has voting rights that entitle the preferred shareholders to vote with the common shareholders as if the preferred stock had converted to common. Both the conversion ratio of the preferred into common (9.6:1)and the number of shares outstanding is subject to revision upon reverse stock dividends or splits that reduce the total shares outstanding.

The Series C Preferred Stock has no stated dividend rate.  The Series C Preferred Stock also has voting rights that entitle the preferred shareholders to vote with the common shareholders as if the preferred stock had converted to common. The conversion ratio of the preferred into common is not subject to revision upon reverse stock dividends or splits that reduce the total shares outstanding.  The 103,143 Series C Preferred Stock was issued on February 21, 2008.  These Series C Preferred shares are convertible into 36,100,000 common shares at the rate of 350:1.  On August 15, 2008 the articles of designation for the Series C Preferred Stock were amended to limit the conversion to common shares to 10% of the holders’ original holdings in any quarter.  During the nine months ended September 30, 2013 and September 30, 2012, respectively, 1,743 and 1,853 Series C Preferred Stock shares were converted into 610,015 and 720,020 shares of common stock, respectively.

12

ARRAYIT CORPORATION

NOTES TO CONSOLIDATED UNAUDITED STATEMENTS

September 30, 2013

NOTE 13 – STOCKHOLDERS’ EQUITY

	TOTAL ARRAYIT CORPORATION STOCKHOLDERS' EQUITY (DEFICIENCY)
															Additional
	Preferred Series A				Preferred Series C						Common Stock				Paid In			Retained
Description	Number		Dollar		Number			Dollar			Number		Dollar		Capital			Earnings			Total
Balance, December 31, 2012		22,034	$	22		88,888		$	89			28,179,096	$	27,988	$	16,645,345		$	(24,315,589	)	$	(7,642,145	)
Convert Preferred C to Common						(1,743	)		(2	)		610,015		610		(608	)					-
Common Stock and Warrants Issued for Cash												1,346,154		1,346		173,654						175,000
Common Stock Issued for Cash												100,000		100		17,900						18,000
Common Stock Issued to Satisfy Debt Obligation of Avant Diagnostics, Inc.												500,000		500		59,500						60,000
Cashless Exercise of Warrant												184,350		184		(184	)
Net income for the nine months ended September 30, 2013																			134,737			134,737
Balance, September 30, 2013 (unaudited)		22,034	$	22		87,145		$	87			30,919,615	$	30,728	$	16,895,607		$	(24,180,852	)	$	(7,254,408	)

13

ARRAYIT CORPORATION

NOTES TO CONSOLIDATED UNAUDITED STATEMENTS

September 30, 2013

NOTE 14 – INCOME TAXES

At September 30, 2013 and December 31, 2012, the Company had net operating loss (NOL) carry-forwards available to offset future taxable income of approximately $24 million. The utilization of the NOL carry-forwards is dependent upon the tax laws in effect at the time the NOL carry-forwards can be utilized. It is likely that utilization of the NOL carry-forwards are limited based on changes in control. A valuation allowance of approximately $9.4 million and $9.5 million has been recorded against the deferred tax asset as of September 30, 2013 and December 31, 2012, respectively. The NOL carry-forwards will fully expire in 2032.

NOTE 15 - COMMITMENTS AND CONTINGENCIES

Long Term Lease Commitments

The Company leases its office facility in Sunnyvale, California under operating leases that expire November 30, 2013.   The company expects to extend this lease for one additional month, at a cost to be determined.

Future minimum lease payments as of September 30, 2013 are as follows:

YEAR ENDING 2013                   $24,674

Rent expense was $113,033 and $147,927 for the nine months ended September 30, 2013 and 2012, respectively.

NOTE 16 – SUBSEQUENT EVENTS

Sid Taubenfeld, R.Ph, was appointed a member of the Registrant’s Board of Directors, effective October 14, 2013.

On October 18, 2013, Arrayit Corporation raised $1,000,000 of working capital from a group of accredited investors.  The sale and issuance of the securities discussed above were determined to be exempt from registration in reliance on Rule 506(b) of Regulation D.

On October 21, 2013, Arrayit Corporation entered into a lease agreement with Dollinger Oakmead Associates (the “Landlord”) for a 15,000 square foot research and development space in Sunnyvale, California (the “Lease”). The Lease begins on January 1, 2014, and runs for a period of seven years with a monthly rent of $19,500.00.

On November 6, 2013, Arrayit Corporation entered into a consulting agreement with Diagnostic Oncology Research Organization, Inc. (DOCRO) to pursue CLIA and ISO approval for the new laboratory.

On November 11, 2013, Arrayit Corporation entered into a master services agreement with Diagnostic Oncology Research Organization, Inc. (DOCRO) to begin the pre-IDE submission process for OvaDx®.

At various dates during the quarter ended September 30, 2013, the Company agreed to issue 7,600,000 warrants to purchase shares of its common stock at prices ranging from $0.13 to $1.20 per share for three years. In November 2013, the 7,600,000 warrants were rescinded effective as of the date of their original issuance.  None of the warrants had been exercised.

14

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS

For a description of our significant accounting policies and an understanding of the significant factors that influenced our performance during the nine months ended September 30, 2013, this “Management’s Discussion and Analysis” should be read in conjunction with the Consolidated Unaudited Financial Statements, including the related notes, appearing in Item 1 of this Quarterly Report, as well as the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2012.  The preparation of this Quarterly Report on Form 10-Q requires us to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenue and expenses during the reporting period. There can be no assurance that actual results reported in the future will not differ from those estimates or that revisions of these estimates may not become necessary in the future.

Forward-Looking Statements

This Quarterly Report on Form 10-Q, includes statements that constitute “forward-looking statements.”  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this portion of the Annual Report include, but are not limited to the Company's (i) expectation that certain of its liabilities listed on the balance sheet under the headings "Accounts Payable," "Accrued Liabilities" and "Note Payable" will be retired by issuing stock versus cash during the next 24 months; (ii) expectation that it will continue to devote capital resources to fund continued development of the Arrayit technology; (iii) anticipation that it will incur significant capital expenditures to further its deployment of the Arrayit offerings; and (iv) anticipation of a significant increase in operational and SG&A costs as it accelerates the development and marketing of the Arrayit operations.

Forward-looking statements involve risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results and achievements and cause them to materially differ from those contained in the forward-looking statements include those to be identified in our Annual Report on Form 10-K/A for the year ended December 31, 2012 in the section titled “Risk Factors,” as well as other factors that we are currently unable to identify or quantify, but may exist in the future.

In addition, the foregoing factors may generally affect our business, results of operations and financial position.  Forward-looking statements speak only as of the date the statement was made.  We do not undertake and specifically decline any obligation to update any forward-looking statements.

Results of Operations

Comparison of Operating Results –Three Months Ended September 30, 2013 and 2012

Gross revenues for the three months ended September 30, 2013 and 2012 were $829,201 and $547,233, respectively, representing a 51.5% increase in gross revenues for the period.  The Company shipped more laboratory instruments, including a TissueMax Microarray Printer, and increased sales of SuperEpoxy 3 Substrates during the three months ended September 30, 2013.  The Company also increased sales of commodity chemicals by 74% over the third quarter of 2012.

The cost of sales for the three months ended September 30, 2013 and 2012 were $522,211 and $252,003, respectively resulting in gross profit for the period of $306,990 and $295,230, respectively.  The Company’s cost of sales is dependent upon product mix.  During the third quarter of 2013, the gross margin was 37% versus 54% for the third quarter of 2012.  The Company sold more commodity chemicals in the third quarter of 2013, which have a lower gross margin percentage than the microarray manufacturing instruments and consumables that were sold in the third quarter ended September 30, 2012.

15

Selling, general and administrative expenses for the three months ended September 30, 2013 and 2012 were $259,885 and $297,745, respectively.  The decrease of $37,860 is largely attributable to a reduction in consulting fees incurred during the three months ended September 30, 2013 versus the three months ended September 30, 2012.

Legal expenses of $15,566 for the three months ended September 30, 2013 were mostly attributable to litigation with Baker Hughes against our subsidiary TeleChem International, Inc. and Arrayit Corporation, and to legal review of the new lease agreement.  Legal expenses of $8,331 for the three months ended September 30, 2012 were mostly attributable to litigation with Baker Hughes.  Baker Hughes judgment against TeleChem International, Inc. and Arrayit Corporation was settled on October 24, 2013 and the Company expects to record a gain on extinguishment of debt in the fourth quarter 2013.

Net income from operations was $22,605 for the three months ended September 30, 2013, compared with a net loss from operations of $11,617 for the three months ended September 30, 2012.  The Company raised $175,000 of working capital during the last few weeks of the quarter, which allowed the Company to purchase manufacturing raw materials and begin fulfilling backorders.

Interest expense was $57,086 for the three months ended September 30, 2013, compared to $27,859 for the three months ended September 30, 2012.  The increase in interest costs was the result of accruing additional legal judgment interest and to accruing third party and related party notes payable.

Other income for the three months ended September 30, 2013 includes gain on extinguishment of liabilities of $6,168.

Comparison of Operating Results –Nine Months Ended September 30, 2013 and 2012

Gross revenues for the nine months ended September 30, 2013 and 2012 were $2,374,789 and $1,850,935, respectively, representing a 28% increase in gross revenues for the period.  The Company was able to fulfill some backorders, and attributes the increase in gross revenues to fulfilling orders for instruments, in particular TissueMax Tissue Microarrayer, SpotBot and SpotBot Extreme Microarray Printers and SpotWare Colorimetric Scanners.  The Company also increased sales for substrates and commodity chemicals.

The cost of sales for the nine months ended September 30, 2013 and 2012 were $1,354,619 and $966,185, respectively resulting in gross profit for the period of $1,020,170 and $884,750, respectively.  The Company’s cost of sales is dependent upon product mix.  During the nine months ended September 30, 2013, the gross margin was 43% versus 48% for the nine months ended September 30, 2012.  Gross margin decreased slightly over the three periods as the Company’s higher sales of more high-throughput instruments during the first three months of 2013 were offset by higher sales of commodity chemicals in the second quarter of 2013, which have a lower gross margin percentage.

Selling, general and administrative expenses for the nine months ended September 30, 2013 and 2012 were $744,475 and $2,037,425, respectively.  The decrease of $1,280,982 is largely attributable to a reduction in consulting fees incurred during the nine months ended September 30, 2013.

Legal expenses of $53,473 for the nine months ended September 30, 2013 were mostly attributable to litigation with Baker Hughes against our subsidiary TeleChem International, Inc. and Arrayit Corporation, and to patent maintenance expenses.  Legal expenses of $51,917 for the nine months ended September 30, 2012 were mostly attributable to litigation with Baker Hughes.  Baker Hughes judgment against TeleChem International, Inc. and Arrayit Corporation was released on October 25, 2013 and the Company expects to record a gain on extinguishment of debt in the fourth quarter 2013.

16

Net income from operations was $134,736 for the nine months ended September 30, 2013, compared with a net loss from operations of $1,353,171 for the nine months ended September 30, 2012.  The increase in net operating income is due primarily to an increase in sales and a large decrease in consulting fees.

Interest expense was $249,039 for the nine months ended September 30, 2013, compared to $122,358 for the nine months ended September 30, 2012.  The increase in interest costs was the result of additional interest accrued related to judgment settlements and third party and related party notes payable.

Other income for the nine months ended September 30, 2013 includes gain on extinguishment of liabilities of $171,702.

Liquidity and Capital Resources

Cash flows used in operations were $91,052 for the nine months ended September 30, 2013, and cash provided by operations was $88,922 for the nine months ended September 30, 2012. As of September 30, 2013, we had a working capital deficiency of $7,294,933 and an accumulated deficit of $24,180,850.  The working capital deficiency, in addition to amounts payable in the normal course of business, is primarily attributable to accrued legal expenses, deferred compensation, and judgment interest.

At September 30, 2013, the Company was working on a private placement memorandum, but had no commitments, understandings or arrangements for additional working capital.  On October 18, 2013, Arrayit Corporation raised $1,000,000 of working capital from a group of accredited investors.  The sale and issuance of the securities discussed above were determined to be exempt from registration in reliance on Rule 506(b) of Regulation D.  We are not aware of any other events or uncertainties that have a material impact upon our short-term or long-term liquidity.

We estimate that we may require approximately $2 million over the next twelve (12) months to meet our expenses and to expand current operations to meet customer demands for our products and services.  We may require additional funds over the next eighteen (18) months to assist in realizing our business objectives and for continuing research and development.  The amount and timing of additional funds required will be dependent on a variety of factors and cannot be determined at this time.  The Company has been successful in paying its operating costs and funding its development from operations supplemented by short term borrowings from officers and third parties.   We cannot be certain that we will be able to raise any additional capital to fund our ongoing operations.

Even if we cannot raise additional capital, we believe that we will be able to continue operations for the next 12 months, based on the funding currently provided and revenues that we anticipate generating in the

near future.   Our investors should assume that any additional funding may cause substantial dilution to current stockholders. In addition, we may not be able to raise additional funds on favorable terms, if at all.

Source of Liquidity

During the nine months ended September 30, 2013, the Company raised $175,000 of working capital from an accredited investor, and also relied upon short term loans and extended terms from its creditors to finance its operations.

On October 18, 2013, Arrayit Corporation raised $1,000,000 of working capital from a group of accredited investors.  The sale and issuance of the securities discussed above were determined to be exempt from registration in reliance on Rule 506(b) of Regulation D.

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements.

17

Forward-Looking Statements

This document contains forward-looking statements that involve risks and uncertainties. We use words such as anticipate, believe, plan, expect, future, intend and similar expressions to identify such forward-looking statements. You should not place too much reliance on these forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures

Disclosure controls and procedures are designed with an objective of ensuring that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission. Disclosure controls also are designed with an objective of ensuring that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, in order to allow timely consideration regarding required disclosures.

The evaluation of our disclosure controls by our chief executive officer, who is also our acting chief financial officer, included a review of the controls’ objectives and design, the operation of the controls, and the effect of the controls on the information presented in this Quarterly Report. Our management, including our chief executive officer, does not expect that disclosure controls can or will prevent or detect all errors and all fraud, if any. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Also, projections of any evaluation of the disclosure controls and procedures to future periods are subject to the risk that the disclosure controls and procedures may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Based on this review and evaluation as of the end of the period covered by this Form 10-Q, and subject to the inherent limitations all as described above, our chief executive officer, who is also our acting chief financial officer, has concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) contain material weaknesses and are not effective.

A material weakness is a significant deficiency, or a combination of significant deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

The material weaknesses we have identified are the direct result of a lack of adequate staffing in our accounting department. Currently, our chief executive officer and a controller have sole responsibility for receipts and disbursements. We do not employ any other parties to prepare the periodic financial statements and public filings. Reliance on these limited resources impairs our ability to provide for a proper segregation of duties and the ability to ensure consistently complete and accurate financial reporting, as well as disclosure controls and procedures. As we grow, and as resources permit, we project that we will hire such additional competent financial personnel to assist in the segregation of duties with respect to financial reporting, and Sarbanes-Oxley Section 404 compliance.

(b) Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the quarter.

18

PART II – OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

On October 24, 2013, Baker Hughes and TeleChem International, Inc. and Arrayit Corporation reached agreement to settle Case 106-CV-075502.  Baker Hughes accepted payment or performance other than that specified in the judgment in full satisfaction of the judgment. On October 25, 2013, Baker Hughes filed an acknowledgement of full satisfaction of the judgment in Case 106-CV-075502, and released TeleChem International, Inc and Arrayit Corporation from this judgment.  The Company expects to record a gain on extinguishment of debt with regard to this matter in the fourth quarter 2013.

On March 13, 2013, Plaintiffs Recap Marketing and Consulting LLP sued Defendants Arrayit Corporation in Fort Bend County Texas Case No. 13-DCV-204747 for breach of contract with regard to warrants to purchase common stock.  Recap seeks damages or specific performance, exemplary damages, costs of court and reasonable attorney’s fees.  On April 16, 2013, the Company’s counsel submitted an unopposed motion to transfer venue to Harris County Texas and, subject to the motion to transfer venue, original answer denying the allegations and offered the affirmative defences of failure of condition precedent and expiration of contract, estoppel, failure of consideration and waiver, and in the alternative that the number of shares is incorrect.  The parties attended a voluntary mediation conference on September 18, 2013, but were unable to reach a settlement agreement.  The case is currently scheduled for trial in July of 2014.

There are no other legal proceedings, although we may, from time to time, be party to certain legal proceedings and other various claims and lawsuits in the normal course of our business, which, in the opinion of management, are not material to our business or financial condition.

ITEM 1A – RISKS FACTORS

Not required for smaller reporting companies.

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

NONE

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

NONE

ITEM 4 – REMOVED AND RESERVED

NONE

ITEM 5 – OTHER INFORMATION

NONE

19

ITEM 6 – EXHIBITS

31.1	Certification of Chief Executive Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes - Oxley Act of 2002. (Filed herewith)
32.1	Certification of Chief Executive Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Filed herewith)

20

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Arrayit Corporation
Dated: November 19, 2013	By:	/s/ RENE A. SCHENA
		Rene A. Schena
		Chairman and Director

21

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Rene A. Schena certify that:

1. I have reviewed this Quarterly Report on Form 10-Q Arrayit Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 19, 2013	/s/ Rene A. Schena
	Rene A. Schena
	Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Rene A. Schena certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Arrayit Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 19, 2013	/s/ Rene A. Schena
	Principal Accounting Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Arrayit Corporation. (the “Company”) on Form 10-Q for the period ending September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rene A. Schena certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 19, 2013	/s/ Rene A. Schena
	Chief Executive Officer

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Arrayit Corporation. (the “Company”) on Form 10-Q for the period ending September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rene A. Schena certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 19, 2013	/s/ Rene A. Schena
	Principal Accounting Officer

XML

12. CONVERTIBLE PREFERRED STOCK

9 Months Ended

Sep. 30, 2013

Equity [Abstract]

CONVERTIBLE PREFERRED STOCK

Convertible Preferred Stock

The Series A Preferred Stock has no stated dividend rate and has a liquidation preference of $.001 per share. The Series A Preferred Stock also has voting rights that entitle the preferred shareholders to vote with the common shareholders as if the preferred stock had converted to common. Both the conversion ratio of the preferred into common (9.6:1)and the number of shares outstanding is subject to revision upon reverse stock dividends or splits that reduce the total shares outstanding.

The Series C Preferred Stock has no stated dividend rate.  The Series C Preferred Stock also has voting rights that entitle the preferred shareholders to vote with the common shareholders as if the preferred stock had converted to common. The conversion ratio of the preferred into common is not subject to revision upon reverse stock dividends or splits that reduce the total shares outstanding.  The 103,143 Series C Preferred Stock was issued on February 21, 2008.  These Series C Preferred shares are convertible into 36,100,000 common shares at the rate of 350:1.  On August 15, 2008 the articles of designation for the Series C Preferred Stock were amended to limit the conversion to common shares to 10% of the holders’ original holdings in any quarter.  During the nine months ended September 30, 2013 and September 30, 2012, respectively, 1,743 and 1,853 Series C Preferred Stock shares were converted into 610,015 and 720,020 shares of common stock, respectively.

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]
Total Revenues	$ 829,201	$ 547,233	$ 2,374,789	$ 1,850,935
Cost of Sales	522,211	252,003	1,354,619	966,185
Gross Margin	306,990	295,230	1,020,170	884,750
Selling, General and Administrative	259,885	297,745	744,475	2,037,425
Research and Development	8,934	771	10,149	26,221
Legal Expense	15,566	8,331	53,473	51,917
Income (Loss) from operations	22,605	(11,617)	212,073	(1,230,813)
Interest expense	(57,086)	(27,859)	(249,039)	(122,358)
Gain on extinguishment of liabilities	6,168		171,702
Net income (loss)	28,313	(39,476)	134,736	(1,353,171)
Less: Net loss attributable to the non-controlling interest		(44,407)		(460,813)
Net Income (Loss) attributable to common stockholders	$ 28,313	$ 4,931	$ 134,736	$ (892,358)
Income (Loss) per share - basic	$ 0	$ 0	$ 0	$ (0.03)
Income (Loss) per share - diluted	$ 0	$ 0	$ 0	$ (0.03)
Basic weighted average number of common shares	30,085,700	27,803,584	28,948,749	27,434,176
Diluted weighted average number of common shares	61,290,190	27,803,584	59,838,501	27,434,176

XML

5. ACCOUNTS RECEIVABLE SOLD WITH RECOURSE

9 Months Ended

Sep. 30, 2013

Receivables [Abstract]

ACCOUNTS RECEIVABLE SOLD WITH RECOURSE

Pursuant to an agreement dated July 5, 2007, the Company has sold some of its Accounts Receivable to a financial institution with full recourse.  The financial institution retains a 15% portion of the proceeds from the receivable sales as reserves, which are released to the Company as the Receivables are collected.  The maximum commitment under this facility is $450,000, and is limited to receivables that are less than 31 days outstanding. The facility bears interest at 16% at September 30, 2013, and is secured by an unconditional guarantee of the Company and a first charge against the Accounts Receivable.  At September 30, 2013, the balance outstanding under the recourse contracts was $169,795 net of a hold back reserve of $164,769 (December 31, 2012, $229,706 net of a hold back reserve of $86,984).  Because of the Company’s credit policies, repossession losses and refunds in the event of default have not been significant and losses under the present recourse obligations are not expected to be significant, it is at least reasonably possible that the Company’s estimate will change within the near term.

XML

4. ACCOUNTS RECEIVABLE (Tables)

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Accounts Receivable

	September 30, 2013			December 31, 2012
Gross accounts receivable	$	649,255		$	590,449
Less:
Allowance for doubtful accounts		(133,000	)		(133,000	)
Loan value of receivables sold   with recourse		(169,795	)		(229,706	)
Total	$	346,460		$	227,743

XML

13. STOCKHOLDERS EQUITY

9 Months Ended

Sep. 30, 2013

Equity [Abstract]

STOCKHOLDERS EQUITY

	TOTAL ARRAYIT CORPORATION STOCKHOLDERS' EQUITY (DEFICIENCY)
															Additional
	Preferred Series A				Preferred Series C						Common Stock				Paid In			Retained
Description	Number		Dollar		Number			Dollar			Number		Dollar		Capital			Earnings			Total
Balance, December 31, 2012		22,034	$	22		88,888		$	89			28,179,096	$	27,988	$	16,645,345		$	(24,315,589	)	$	(7,642,145	)
Convert Preferred C to Common						(1,743	)		(2	)		610,015		610		(608	)					-
Common Stock and Warrants Issued for Cash												1,346,154		1,346		173,654						175,000
Common Stock Issued for Cash												100,000		100		17,900						18,000
Common Stock Issued to Satisfy Debt Obligation of Avant Diagnostics, Inc.												500,000		500		59,500						60,000
Cashless Exercise of Warrant												184,350		184		(184	)
Net income for the nine months ended September 30, 2013																			134,737			134,737
Balance, September 30, 2013 (unaudited)		22,034	$	22		87,145		$	87			30,919,615	$	30,728	$	16,895,607		$	(24,180,852	)	$	(7,254,408	)

XML

10. ROYALTY OBLIGATIONS (Details Narrative) (Arrayit Scientific Solutions, Inc.)	Sep. 30, 2013
Arrayit Scientific Solutions, Inc.
Royalty Percentage	5.00%

XML

8. DEBT (Tables)

9 Months Ended

Sep. 30, 2013

Debt Disclosure [Abstract]

Notes Payable

	September 30, 2013		December 31, 2012
NOTES PAYABLE - ARRAYIT CORP.
Notes payable, interest at 10%, which was due August 10, 2010 and is now past due, secured by 1,000,000 shares out of the Company's common stock, pledged to the private lender without compensation by the Company's Chairman.  Interest is being accrued at 25% default rate.	$	305,938	$	275,000
Note payable, 0% interest, due on demand together with 75,000 shares in the form of common stock warrants		15,000		15,000
Notes payable, interest at 8%, unsecured due on demand from Arrayit creditors		31,082		30,749
Notes payable, interest at rates varying from 8% to 10%, unsecured due on demand from the former TeleChem shareholders and their families.		538,637		608,520
Total notes payable, including related parties	$	890,657	$	929,269
Short Term Debt	$	890,657	$	929,269
Long Term Debt	$	-	$	-

XML

7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2013

Payables and Accruals [Abstract]

Accounts payable and accrued liabilites

	September 30, 2013		December 31, 2012
ACCOUNTS PAYABLE
Trade vendors	$	1,512,038	$	1,488,622
Professional advisors		2,979,852		3,059,594
Total Accounts Payable		4,491,890		4,548,216
ACCRUED LIABILITIES
Accrued salaries and wages		1,111,649		1,127,089
Judgment interest		628,698		482,404
Other		409,427		409,427
Total Accrued Liabilities		2,149,774		2,018,920
TOTAL	$	6,641,664	$	6,567,136

XML

6. FIXED ASSETS - Property and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Fixed Assets - Cost	$ 333,319	$ 311,157
Accumulated Depreciation	(311,157)	(311,157)
Property and equipment, net	$ 22,162

XML

13. STOCKHOLDERS’ EQUITY (Details) (USD $)	3 Months Ended		9 Months Ended				9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013 Preferred Series A	Dec. 31, 2012 Preferred Series A	Sep. 30, 2013 Preferred Series C	Sep. 30, 2013 Common Stock	Sep. 30, 2013 Additional Paid-In Capital	Sep. 30, 2013 Retained Earnings
Beginning Balance, Shares					22,034	22,034	88,888	28,179,096
Beginning Balance, Amount			$ (7,642,145)		$ 22	$ 22	$ 89	$ 27,988	$ 16,645,345	$ (24,315,589)
Convert Preferred C to Common, Shares							(1,743)	610,015
Convert Preferred C to Common, Amount							(2)	610	(608)
Common Stock and Warrants Issued for Cash, Shares								1,346,154
Common Stock and Warrants Issued for Cash, Amount			175,000					1,346	173,654
Common Stock Issued for Cash, Shares								100,000
Common Stock Issued for Cash, Amount			18,000					100	17,900
Common Stock Issued to Satisfy Debt Obligation of Avant Diagnostics, Inc., Shares								500,000
Common Stock Issued to Satisfy Debt Obligation of Avant Diagnostics, Inc., Amount			60,000					500	59,500
Cashless Exercise of Warrant, Shares								184,350
Cashless Exercise of Warrant, Amount								184	(184)
Net (loss)	28,313	(39,476)	134,736	(1,353,171)						134,737
Ending Balance, Shares					22,034	22,034	87,145	30,919,615
Ending Balance, Amount	$ (7,254,406)		$ (7,254,406)		$ 22	$ 22	$ 87	$ 30,728	$ 16,895,607	$ (24,180,852)

XML

3. GOING CONCERN (Details Narrative) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working Capital Deficit	$ 7,294,933
Accumulated Deficit	$ (24,180,850)	$ (24,315,589)

XML

6. FIXED ASSETS (Tables)

9 Months Ended

Sep. 30, 2013

Property, Plant and Equipment [Abstract]

Property and Equipment

	September 30, 2013			December 31, 2012
Fixed Assets – Cost	$	333,319		$	311,157
Less Accumulated Depreciation		(311,157	)		(311,157	)
Total	$	22,162		$	-

XML

1. ORGANIZATION AND BUSINESS OPERATIONS

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

ORGANIZATION AND BUSINESS OPERATIONS

Arrayit Corporation (the “Company” or “Arrayit”) is a Nevada “C” Corporation that entered into the life sciences industry in 1996.  Arrayit is a leading edge developer, manufacturer and marketer of next-generation life science tools and integrated systems for the large scale analysis of genetic variation, biological function and diagnostics. Using Arrayit’s proprietary and patented technologies, the Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping, gene expression and protein analysis markets, and the Company expects to enter the market for manufacturing molecular diagnostics.

Arrayit has earned respect as a leader in the health care and life sciences industries with its proven expertise in three key areas:  the development and support of microarray tools and components, custom printing and analysis of microarrays for research, and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states.  As a result, Arrayit has provided tools and services to thousands of the leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies worldwide.

Arrayit has a December 31 year end.

Arrayit’s principal office is in Sunnyvale, California. Arrayit presently has nine employees.

Interim financial statements

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X, and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ equity in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Arrayit’s Annual Report filed with the SEC on Form 10-K/A. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the consolidated financial statements, which would substantially duplicate the disclosures contained in the audited financial statements for fiscal year 2012 as reported in Form 10-K/A, have been omitted.

XML

3. GOING CONCERN

9 Months Ended

Sep. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

The accompanying consolidated financial statements of the Company were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has large working capital and accumulated deficits. At September 30, 2013, Arrayit had a working capital deficit of $7,294,933 and an accumulated deficit of $24,180,850.  Management believes that current available resources will not be sufficient to fund the Company’s planned expenditures over the next 12 months. The Company’s ability to continue to meet its obligations and to achieve its business objectives is dependent upon, among other things, raising additional capital or generating sufficient revenue in excess of costs. At such time as the Company requires additional funding, the Company will seek to raise such additional funding from various possible sources, including its parent company, the public equity market, private financings, sales of assets, collaborative arrangements and debt. If the Company raises additional capital through the issuance of equity securities or securities convertible into equity, stockholders will experience dilution, and such securities may have rights, preferences or privileges senior to those of the holders of common stock or convertible senior notes. If the Company raises additional funds by issuing debt, the Company may be subject to limitations on its operations, through debt covenants or other restrictions. If the Company obtains additional funds through arrangements with collaborators or strategic partners, the Company may be required to relinquish its rights to certain technologies or products that it might otherwise seek to retain. There can be no assurance that the Company will be able to raise additional funds, or raise them on acceptable terms. If the Company is unable to obtain financing on acceptable terms, it may be unable to execute its business plan, the Company could be required to delay or reduce the scope of its operations, and the Company may not be able to pay off its obligations, if and when they come due.

These factors create substantial doubt about Arrayit’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability or classification of recorded assets and liabilities or other adjustments that may be necessary should the Company not be able to continue as a going concern.

The ability of Arrayit to continue as a going concern is dependent on Arrayit generating cash from the sale of its common stock or obtaining debt financing and attaining future profitable operations. Management's plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance Arrayit will be successful in these efforts.

XML

6. FIXED ASSETS

9 Months Ended

Sep. 30, 2013

Property, Plant and Equipment [Abstract]

FIXED ASSETS

Property and equipment consisted of the following:

	September 30, 2013			December 31, 2012
Fixed Assets – Cost	$	333,319		$	311,157
Less Accumulated Depreciation		(311,157	)		(311,157	)
Total	$	22,162		$	-

Depreciation expense totaled $0 and $9,818, respectively, for the nine months ended September 30, 2013 and 2012. 

XML

4. ACCOUNTS RECEIVABLE

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

ACCOUNTS RECEIVABLE

Accounts receivable are shown net of an Allowance for Doubtful Accounts.  As more fully explained in Note 5 below, accounts receivable has been reduced by Accounts Receivable loans sold with recourse.

	September 30, 2013			December 31, 2012
Gross accounts receivable	$	649,255		$	590,449
Less:
Allowance for doubtful accounts		(133,000	)		(133,000	)
Loan value of receivables sold   with recourse		(169,795	)		(229,706	)
Total	$	346,460		$	227,743

XML

15. INCOME TAXES (Details Narrative) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Net operating loss carry-forward	$ 2.4	$ 2.4
Change in valuation allowance	$ 203.2

XML

9. WARRANTS AND OPTIONS (Tables)

9 Months Ended

Sep. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Options and Warrants outstanding

	Number of Options and Warrants		Weighted Average Exercise Price Per Share
Outstanding at December 31, 2012		1,915,000	$	0.08
Granted		1,346,154	$	0.17
Cancelled/forfeited		-		-
Expired		1,265,000	$	.05
Exercised		650,000	$	.30
Outstanding at Sept 30, 2013		1,346,154	$	0.17

XML

4. ACCOUNTS RECEIVABLE (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accounts and Notes Receivable, Net [Abstract]
Gross accounts receivable	$ 649,255	$ 590,449
Allowance for doubtful accounts	(133,000)	(133,000)
Loan value of receivables sold with recourse (see note 5)	(169,795)	(229,706)
Accounts receivable	$ 346,460	$ 227,743

XML

9. WARRANTS AND OPTIONS (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2013
Number of Options and Warrants
Outstanding beginning of period, Number of Options	1,915,000
Granted, Number of shares	1,346,154
Cancelled/forfeited, number of shares
Expired, Number of shares	1,265,000
Exercised, Number of shares	650,000
Outstanding at end of period, Number of Options	1,346,154
Weighted Average Exericse Price
Outstanding at beginning of period, Weighted average exercise price	$ 0.08
Granted, Weighted average exercise price	$ 0.17
Cancelled/forfeited, number of shares
Expired, Weighted average exercise price	$ 0.05
Exercised, Weighted average exercise price	$ 0.30
Outstanding atend of period, Weighted average exercise price	$ 0.17

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Allowance for doubtful accounts	$ 133,000	$ 133,000
Common Stock
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	480,000,000	480,000,000
Common stock, shares issued	30,918,453	28,179,096
Common stock, shares outstanding	30,918,453	28,179,096
Preferred Stock
Preferred stock, shares authorized	0.001	0.001
Preferred stock, shares issued	20,000,000	20,000,000
Preferred Class A
Preferred stock, shares authorized	0.001	0.001
Preferred stock, shares outstanding	22,034	22,034
Preferred Class C
Preferred stock, shares authorized	0.001	0.001
Preferred stock, shares outstanding	87,146	88,888

XML

9. WARRANTS AND OPTIONS

9 Months Ended

Sep. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

WARRANTS AND OPTIONS

The following table summarizes options and warrants outstanding at September 30, 2013:

	Number of Options and Warrants		Weighted Average Exercise Price Per Share
Outstanding at December 31, 2012		1,915,000	$	0.08
Granted		1,346,154	$	0.17
Cancelled/forfeited		-		-
Expired		1,265,000	$	.05
Exercised		650,000	$	.30
Outstanding at Sept 30, 2013		1,346,154	$	0.17

In June 2013, the Company completed a unit offering of its common stock. Subscribers purchased units at $0.13 per unit with each unit consisting of one share of common stock and a warrant to purchase an additional share at prices ranging from $0.15 to $0.18 per share for three years. The Company raised $175,000 and issued 1,346,154 shares of common stock and 1,346,154 warrants to purchase common stock under this offering. None of the warrants have been exercised.

In September 2013, a warrant holder exercised 650,000 warrants with exercise prices ranging from $0.20 to $0.35 per share and received 184,350 common shares through a cashless exercise at the market price of $0.42 per share.

At various dates during the quarter ended September 30, 2013, the Company agreed to issue 7,600,000 warrants to purchase shares of its common stock at prices ranging from $0.13 to $1.20 per share for three years. In November 2013, the 7,600,000 warrants were rescinded effective as of the date of their original issuance.  None of the warrants had been exercised.

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ 134,736	$ (1,353,171)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation		9,818
Stock paid for services		36,150
Gain on extinguishment of liabilities	(171,702)
Increase in non-controlling interest		1,080,868
Bad Debt Recovery	(5,312)
Provision for bad debt	38,962
Changes in operating assets and liabilities
Accounts receivable	(132,452)	78,372
Inventory	(127,948)	(172,053)
Accounts payable and accrued liabilities	76,365	341,094
Bank overdraft	(120,308)	26,456
Due to related parties	(51,500)	(29,000)
Accrued interest	250,838	70,388
Customer deposits	17,269
Net cash provided by (used in) operating activities	(91,052)	88,922
Cash flows from investing activities:
Cash paid for purchase of fixed assets	(1,124)
Net cash used in investing activities	(1,124)
Cash flows from financing activities:
Proceeds from loans
Proceeds from issuance of common stock	193,000
Proceeds from notes payable		85,320
Repayment of notes payable	(100,535)	(152,059)
Net cash provided by (used by) financing activities	92,465	(66,739)
Net increase in cash	289	22,183
Cash, beginning of period	518	1,519
Cash, end of period	807	23,702
Supplemental cash flow information:
Cash paid for interest

XML

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets:
Cash	$ 807	$ 518
Accounts receivable	346,460	227,743
Inventory	444,755	316,807
Prepaid expenses	2,250	2,250
Total current assets	794,272	547,318
Fixed assets, net	22,162
Deposits	18,365	18,365
Total assets	834,799	565,683
Current liabilities:
Accounts payable and accrued liabilities	6,641,664	6,567,136
Bank overdraft	9,187	129,495
Due to related parties	525,533	577,033
Customer deposits	22,164	4,895
Notes payables, current portion including related parties	890,657	929,269
Total current liabilities	8,089,205	8,207,828
Notes payable, long term
Total liabilities	8,089,205	8,207,828
Stockholders' Deficit
Preferred stock, $0.001 par value; 20,000,000 shares authorized;	22	22
Common stock	30,728	27,988
Additional paid-in capital	16,895,607	16,645,345
Accumulated deficit	(24,180,850)	(24,315,589)
Total stockholders' deficit	(7,254,406)	(7,642,145)
Total liabilities and stockholders' deficit	(834,799)	565,683
Preferred Class A
Stockholders' Deficit
Preferred stock, $0.001 par value; 20,000,000 shares authorized;	87	89
Preferred Class C
Stockholders' Deficit
Preferred stock, $0.001 par value; 20,000,000 shares authorized;	$ 30,728	$ 27,988

XML

13. STOCKHOLDERS EQUITY (Tables)

9 Months Ended

Sep. 30, 2013

Equity [Abstract]

Outstanding warrants and options for common stock

	TOTAL ARRAYIT CORPORATION STOCKHOLDERS' EQUITY (DEFICIENCY)
															Additional
	Preferred Series A				Preferred Series C						Common Stock				Paid In			Retained
Description	Number		Dollar		Number			Dollar			Number		Dollar		Capital			Earnings			Total
Balance, December 31, 2012		22,034	$	22		88,888		$	89			28,179,096	$	27,988	$	16,645,345		$	(24,315,589	)	$	(7,642,145	)
Convert Preferred C to Common						(1,743	)		(2	)		610,015		610		(608	)					-
Common Stock and Warrants Issued for Cash												1,346,154		1,346		173,654						175,000
Common Stock Issued for Cash												100,000		100		17,900						18,000
Common Stock Issued to Satisfy Debt Obligation of Avant Diagnostics, Inc.												500,000		500		59,500						60,000
Cashless Exercise of Warrant												184,350		184		(184	)
Net income for the nine months ended September 30, 2013																			134,737			134,737
Balance, September 30, 2013 (unaudited)		22,034	$	22		87,145		$	87			30,919,615	$	30,728	$	16,895,607		$	(24,180,852	)	$	(7,254,408	)

XML

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN (Tables)

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Susidiaries and percentage ownership

Subsidiary	Date of Incorporation	Business of Entity	Ownership
TeleChem International, Inc.	November 1, 1993	Import, export, manufacturing and distribution of wholesale industrial chemicals	100% owned by Arrayit Corporation
Arrayit Scientific Solutions, Inc.	October 15, 2009	Markets a test for Parkinson’s Disease incorporating the technology and equipment developed by Arrayit Corporation	98% owned by Arrayit Corporation and 2% owned by the former President of Arrayit Scientific Solutions, Inc.
Avant Diagnostics, Inc.	June 2, 2009	Markets a test for Ovarian Cancer incorporating the technology and equipment developed by Arrayit Corporation	42.9% owned by Arrayit Corporation

XML

11. STOCK-BASED COMPENSATION (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Equity [Abstract]
Stock-based compensation	$ 0	$ 36,150
Restricted shares issued	0	106,325

XML

7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Accounts payable and accrued liabilites (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
ACCOUNTS PAYABLE
Trade Vendors	$ 1,512,038	$ 1,488,622
Professional Advisors	2,979,852	3,059,594
Total Accounts Payable	4,491,890	4,548,216
ACCRUED LIABILITIES
Accrued salaries and wages	1,111,649	1,127,089
Judgment Interest	628,698	482,404
Other	409,427	409,427
Total Accrued Liabilities	2,149,774	2,018,920
TOTAL	$ 6,641,664	$ 6,567,136

XML

8. DEBT - Notes Payable (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Notes Payable	$ 890,657	$ 929,629
Short Term Debt	890,657	929,629
Long Term Debt	0	0
Arrayit Corp. | Note 1
Notes Payable	305,938	275,000
Arrayit Corp. | Note 2
Notes Payable	15,000	15,000
Arrayit Corp. | Note 3
Notes Payable	31,082	30,749
Arrayit Corp. | Note 4
Notes Payable	$ 538,637	$ 608,520

XML

8. DEBT

9 Months Ended

Sep. 30, 2013

Debt Disclosure [Abstract]

DEBT

	September 30, 2013		December 31, 2012
NOTES PAYABLE - ARRAYIT CORP.
Notes payable, interest at 10%, which was due August 10, 2010 and is now past due, secured by 1,000,000 shares out of the Company's common stock, pledged to the private lender without compensation by the Company's Chairman.  Interest is being accrued at 25% default rate.	$	305,938	$	275,000
Note payable, 0% interest, due on demand together with 75,000 shares in the form of common stock warrants		15,000		15,000
Notes payable, interest at 8%, unsecured due on demand from Arrayit creditors		31,082		30,749
Notes payable, interest at rates varying from 8% to 10%, unsecured due on demand from the former TeleChem shareholders and their families.		538,637		608,520
Total notes payable, including related parties	$	890,657	$	929,269
Short Term Debt	$	890,657	$	929,269
Long Term Debt	$	-	$	-

XML

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN - Susidiaries and percentage ownership (Details)	9 Months Ended
	Sep. 30, 2013
Arrayit Scientific Solutions, Inc.
Date of Incorporation	Nov. 01, 1993
Ownership	100.00%
Avant Diagnostics, Inc.
Date of Incorporation	Oct. 15, 2009
Ownership	98.00%
Ownership by president	0.20%
TeleChem International, Inc.
Date of Incorporation	Jun. 02, 2009
Ownership	42.90%

XML

16. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payments	$ 24,674
Rent Expense	$ 113,033	$ 147,927

XML

11. STOCK-BASED COMPENSATION

9 Months Ended

Sep. 30, 2013

Equity [Abstract]

STOCK-BASED COMPENSATION

The Company adopted ASC 718 and ASC 505, "Share-Based Payment", to account for its stock options and similar equity instruments issued.  Accordingly, compensation costs attributable to stock options or similar equity instruments granted are measured at the fair value at the grant date, and expensed over the expected vesting period.  ASC 718 and ASC 505 requires excess tax benefits be reported as a financing cash inflow rather than as a reduction of taxes paid.

Operations for the periods ended September 30, 2013 and September 30, 2012 include $0 and $36,150 of stock-based compensation, arising from the granting of 0 and 106,325 unregistered common shares, respectively.  Restricted shares were issued in exchange for services related to website consulting and investor relations. The Company relied upon the exemption under Section 4(2) of the Securities Act.

XML

7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

9 Months Ended

Sep. 30, 2013

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities, consisted of the following:

	September 30, 2013		December 31, 2012
ACCOUNTS PAYABLE
Trade vendors	$	1,512,038	$	1,488,622
Professional advisors		2,979,852		3,059,594
Total Accounts Payable		4,491,890		4,548,216
ACCRUED LIABILITIES
Accrued salaries and wages		1,111,649		1,127,089
Judgment interest		628,698		482,404
Other		409,427		409,427
Total Accrued Liabilities		2,149,774		2,018,920
TOTAL	$	6,641,664	$	6,567,136

XML

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

Basis of Presentation

The following includes a description of subsidiaries and percentage ownership at September 30, 2013:

Subsidiary	Date of Incorporation	Business of Entity	Ownership
TeleChem International, Inc.	November 1, 1993	Import, export, manufacturing and distribution of wholesale industrial chemicals	100% owned by Arrayit Corporation
Arrayit Scientific Solutions, Inc.	October 15, 2009	Markets a test for Parkinson’s Disease incorporating the technology and equipment developed by Arrayit Corporation	98% owned by Arrayit Corporation and 2% owned by the former President of Arrayit Scientific Solutions, Inc.
Avant Diagnostics, Inc.	June 2, 2009	Markets a test for Ovarian Cancer incorporating the technology and equipment developed by Arrayit Corporation	42.9% owned by Arrayit Corporation

The Company had previously consolidated the financial statements of Avant Diagnostics, Inc. as a majority owned subsidiary and this is reflected in the unaudited consolidated financial statements for the three and nine months ended September 30, 2012.  On December 31, 2012, Avant Diagnostics, Inc. issued additional shares of its common stock which reduced the Company’s ownership interest in Avant Diagnostics, Inc. so that the Company no longer had a controlling financial interest.  In accordance with FASB ASC 810-10-40, “Deconsolidation of a Subsidiary or Derecognition of a Group of Assets”, as of December 31, 2012, the Company deconsolidated its majority ownership interest and recognized a non-cash, net gain on the transaction.  Thus, the Company’s September 30, 2013 unaudited financial statements do not include the effect of the financial statements of Avant Diagnostics, Inc.

In July 2013, the Company issued 500,000 shares of its common stock with a market price of $0.12 per share or $60,000 to settle debt of Avant Diagnostics, Inc.  Arrayit Corporation was the guarantor of the debt.  The Company recorded a charge of $38,962 on the transaction and received equipment from Avant Diagnostics, Inc. valued at $21,038.

On December 12, 2011, Arrayit Corporation signed an Agreement and Plan of Distribution with its subsidiary, Avant Diagnostics, Inc., whereby 19,350,000 shares of common stock of Avant Diagnostics (42.9% of the total outstanding) owned by Arrayit Corporation will be distributed ratably to the shareholders of Arrayit Corporation on the record date which will occur upon approval by the SEC of the Form S-1 registration statement to be submitted by Avant Diagnostics, Inc.

Summary of Significant Accounting Policies

Financial Reporting:

The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America. Revenues and expenses are reported on the accrual basis, which means that income is recognized as it is earned and expenses are recognized as they are incurred. Inventories are stated at the lower of cost or market, cost determined on the basis of FIFO. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured.

Management acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that 1) recorded transactions are valid; 2) valid transactions are recorded; and 3) transactions are recorded in the proper period in a timely manner to produce financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

Non-Controlling Interest:

The Company accounts for the non-controlling interest in its subsidiaries under ASC 810-10-45-16, Non-controlling Interest in a Subsidiary.  This standard defines a non-controlling interest, previously called a minority interest, as the portion of equity in a subsidiary not attributable, directly or indirectly, to a parent. The standard requires, among other items, that a non-controlling interest be included in the consolidated statement of financial position within equity separate from the parent's equity; consolidated net income to be reported at amounts inclusive of both the parent's and non-controlling interest’s shares and, separately, the amounts of consolidated net income attributable to the parent and non-controlling interest all on the consolidated statement of operations; and if a subsidiary is deconsolidated, any retained non-controlling equity investment in the former subsidiary be measured at fair value and a gain or loss be recognized in net income based on such fair value.  Additionally, the standard defines a non-controlling interest as a financial instrument issued by a subsidiary that is classified as equity in the subsidiary's financial statements.  A financial instrument issued by a subsidiary that is classified as a liability in the subsidiary's financial statements based on the guidance in other standards is not a controlling interest because it is not an ownership interest.

Recent Accounting Pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

Income/Loss per Common and Common Equivalent Share

The computation of basic income/loss per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents which would arise from their exercise using the treasury stock method and the average market price per share during the year.  The Company determined that the effect of common stock equivalents (Stock Options, Stock Warrants and convertible Series “C” Preferred Shares) outstanding at September 30, 2013 should be included in diluted earnings per common share for the nine months ended September 30, 2013.  The effect of common stock equivalents for the three months ended September 30, 2013 and for the periods in 2012 were anti-dilutive.

XML

5. ACCOUNTS RECEIVABLE SOLD WITH RECOURSE (Details Narrative) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Receivables [Abstract]
Retainer of proceeds of receivables as reserve	15.00%	15.00%
Maximum Commitment	$ 450,000	$ 450,000
Interest rate	16.00%	16.00%
Loan value of receivables sold with recourse (see note 5)	169,795	229,706
Hold back reserve	$ 164,769	$ 86,984

XML

14. INCOME TAXES

9 Months Ended

Sep. 30, 2013

Income Tax Disclosure [Abstract]

INCOME TAXES

At September 30, 2013 and December 31, 2012, the Company had net operating loss (NOL) carry-forwards available to offset future taxable income of approximately $24 million. The utilization of the NOL carry-forwards is dependent upon the tax laws in effect at the time the NOL carry-forwards can be utilized. It is likely that utilization of the NOL carry-forwards are limited based on changes in control. A valuation allowance of approximately $9.4 million and $9.5 million has been recorded against the deferred tax asset as of September 30, 2013 and December 31, 2012, respectively. The NOL carry-forwards will fully expire in 2032.

XML

10. ROYALTY OBLIGATIONS

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

ROYALTY OBLIGATIONS

The Parkinson’s Institute – ARRAYIT SCIENTIFIC SOLUTIONS, INC.

Pursuant to an agreement dated February 9, 2009 between the Company, and The Parkinson's Institute, a California Corporation, Arrayit Scientific Solutions, Inc. is obligated to make payments, of 5% of gross earnings generated from Research derived from the biological specimens from Parkinson's disease patients and control patients provided by the Parkinson's Institute.

There were no revenues generated during the fiscal periods ended September 30, 2013 and hence no obligation to pay any royalties to the Parkinson’s Institute.

XML

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN (Policies)

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Basis of Presentation

The following includes a description of subsidiaries and percentage ownership at September 30, 2013:

Subsidiary	Date of Incorporation	Business of Entity	Ownership
TeleChem International, Inc.	November 1, 1993	Import, export, manufacturing and distribution of wholesale industrial chemicals	100% owned by Arrayit Corporation
Arrayit Scientific Solutions, Inc.	October 15, 2009	Markets a test for Parkinson’s Disease incorporating the technology and equipment developed by Arrayit Corporation	98% owned by Arrayit Corporation and 2% owned by the former President of Arrayit Scientific Solutions, Inc.
Avant Diagnostics, Inc.	June 2, 2009	Markets a test for Ovarian Cancer incorporating the technology and equipment developed by Arrayit Corporation	42.9% owned by Arrayit Corporation

The Company had previously consolidated the financial statements of Avant Diagnostics, Inc. as a majority owned subsidiary and this is reflected in the unaudited consolidated financial statements for the three and nine months ended September 30, 2012.  On December 31, 2012, Avant Diagnostics, Inc. issued additional shares of its common stock which reduced the Company’s ownership interest in Avant Diagnostics, Inc. so that the Company no longer had a controlling financial interest.  In accordance with FASB ASC 810-10-40, “Deconsolidation of a Subsidiary or Derecognition of a Group of Assets”, as of December 31, 2012, the Company deconsolidated its majority ownership interest and recognized a non-cash, net gain on the transaction.  Thus, the Company’s September 30, 2013 unaudited financial statements do not include the effect of the financial statements of Avant Diagnostics, Inc.

In July 2013, the Company issued 500,000 shares of its common stock with a market price of $0.12 per share or $60,000 to settle debt of Avant Diagnostics, Inc.  Arrayit Corporation was the guarantor of the debt.  The Company recorded a charge of $38,962 on the transaction and received equipment from Avant Diagnostics, Inc. valued at $21,038.

On December 12, 2011, Arrayit Corporation signed an Agreement and Plan of Distribution with its subsidiary, Avant Diagnostics, Inc., whereby 19,350,000 shares of common stock of Avant Diagnostics (42.9% of the total outstanding) owned by Arrayit Corporation will be distributed ratably to the shareholders of Arrayit Corporation on the record date which will occur upon approval by the SEC of the Form S-1 registration statement to be submitted by Avant Diagnostics, Inc.

Financial Reporting

The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America. Revenues and expenses are reported on the accrual basis, which means that income is recognized as it is earned and expenses are recognized as they are incurred. Inventories are stated at the lower of cost or market, cost determined on the basis of FIFO. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured.

Management acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that 1) recorded transactions are valid; 2) valid transactions are recorded; and 3) transactions are recorded in the proper period in a timely manner to produce financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

Non-Controlling Interest

The Company accounts for the non-controlling interest in its subsidiaries under ASC 810-10-45-16, Non-controlling Interest in a Subsidiary.  This standard defines a non-controlling interest, previously called a minority interest, as the portion of equity in a subsidiary not attributable, directly or indirectly, to a parent. The standard requires, among other items, that a non-controlling interest be included in the consolidated statement of financial position within equity separate from the parent's equity; consolidated net income to be reported at amounts inclusive of both the parent's and non-controlling interest’s shares and, separately, the amounts of consolidated net income attributable to the parent and non-controlling interest all on the consolidated statement of operations; and if a subsidiary is deconsolidated, any retained non-controlling equity investment in the former subsidiary be measured at fair value and a gain or loss be recognized in net income based on such fair value.  Additionally, the standard defines a non-controlling interest as a financial instrument issued by a subsidiary that is classified as equity in the subsidiary's financial statements.  A financial instrument issued by a subsidiary that is classified as a liability in the subsidiary's financial statements based on the guidance in other standards is not a controlling interest because it is not an ownership interest.

Recent Accounting Pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

Income/Loss per Common and Common Equivalent Shares

The computation of basic income/loss per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents which would arise from their exercise using the treasury stock method and the average market price per share during the year.  The Company determined that the effect of common stock equivalents (Stock Options, Stock Warrants and convertible Series “C” Preferred Shares) outstanding at September 30, 2013 should be included in diluted earnings per common share for the nine months ended September 30, 2013.  The effect of common stock equivalents for the three months ended September 30, 2013 and for the periods in 2012 were anti-dilutive.

XML

15. COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Long Term Lease Commitments

The Company leases its office facility in Sunnyvale, California under operating leases that expire November 30, 2013.   The company expects to extend this lease for one additional month, at a cost to be determined.

Future minimum lease payments as of September 30, 2013 are as follows:

YEAR ENDING 2013                   $24,674

Rent expense was $113,033 and $147,927 for the nine months ended September 30, 2013 and 2012, respectively.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 07, 2013
Document And Entity Information
Entity Registrant Name	Arrayit Corp.
Entity Central Index Key	0001084507
Document Type	10-Q
Document Period End Date	Sep. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,918,453
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2013

XML

16. SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

16. SUBSEQUENT EVENTS

Sid Taubenfeld, R.Ph, was appointed a member of the Registrant’s Board of Directors, effective October 14, 2013.

On October 18, 2013, Arrayit Corporation raised $1,000,000 of working capital from a group of accredited investors.  The sale and issuance of the securities discussed above were determined to be exempt from registration in reliance on Rule 506(b) of Regulation D.

On October 21, 2013, Arrayit Corporation entered into a lease agreement with Dollinger Oakmead Associates (the “Landlord”) for a 15,000 square foot research and development space in Sunnyvale, California (the “Lease”). The Lease begins on January 1, 2014, and runs for a period of seven years with a monthly rent of $19,500.00.

On November 6, 2013, Arrayit Corporation entered into a consulting agreement with Diagnostic Oncology Research Organization, Inc. (DOCRO) to pursue CLIA and ISO approval for the new laboratory.

On November 11, 2013, Arrayit Corporation entered into a master services agreement with Diagnostic Oncology Research Organization, Inc. (DOCRO) to begin the pre-IDE submission process for OvaDx®.

At various dates during the quarter ended September 30, 2013, the Company agreed to issue 7,600,000 warrants to purchase shares of its common stock at prices ranging from $0.13 to $1.20 per share for three years. In November 2013, the 7,600,000 warrants were rescinded effective as of the date of their original issuance.  None of the warrants had been exercised.